FY2025 EPS Estimate for Arcus Biosciences Reduced by Analyst

Arcus Biosciences, Inc. (NYSE:RCUS) – Stock analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Arcus Biosciences in a research note issued on Tuesday, February 18th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($4.69) per share for the year, down from their previous estimate of ($3.54). HC Wainwright has a “Neutral” rating and a $18.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share. HC Wainwright also issued estimates for Arcus Biosciences’ FY2026 earnings at ($5.44) EPS, FY2027 earnings at ($5.62) EPS and FY2028 earnings at ($2.81) EPS.

Several other research firms have also recently issued reports on RCUS. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. Morgan Stanley lowered their price target on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday. Barclays increased their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Finally, Bank of America lowered their price target on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Arcus Biosciences Stock Performance

RCUS stock opened at $11.06 on Friday. The stock has a market capitalization of $1.01 billion, a PE ratio of -3.51 and a beta of 0.84. Arcus Biosciences has a 12-month low of $10.63 and a 12-month high of $20.31. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock’s 50 day simple moving average is $13.92 and its 200 day simple moving average is $15.55.

Institutional Investors Weigh In On Arcus Biosciences

A number of institutional investors have recently bought and sold shares of RCUS. R Squared Ltd purchased a new stake in Arcus Biosciences in the 4th quarter worth $26,000. Point72 Hong Kong Ltd purchased a new stake in Arcus Biosciences in the 3rd quarter worth $47,000. Lazard Asset Management LLC increased its stake in Arcus Biosciences by 3,321.3% in the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after buying an additional 6,078 shares in the last quarter. US Bancorp DE increased its stake in Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after buying an additional 6,615 shares in the last quarter. Finally, Quest Partners LLC increased its stake in Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after buying an additional 9,408 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the completion of the sale, the chief financial officer now owns 60,138 shares in the company, valued at approximately $902,070. This represents a 5.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 12.30% of the stock is currently owned by company insiders.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.